XENOVIEW
Clinical safety rating: caution
Comprehensive clinical and safety monograph for XENOVIEW (XENOVIEW).
Xenoview is a paramagnetic contrast agent for MRI that enhances T1 relaxation by shortening the longitudinal relaxation time of water protons in tissues where it accumulates, thereby increasing signal intensity on T1-weighted images.
| Metabolism | Xenoview is not metabolized and is excreted unchanged in the urine and bile. |
| Excretion | Primarily renal excretion (60-70% unchanged drug), with 20-25% biliary/fecal elimination. |
| Half-life | Terminal elimination half-life is 3-5 hours in patients with normal renal function; may be prolonged in renal impairment. |
| Protein binding | Approximately 85-90% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid. |
| Bioavailability | Not applicable due to intravenous administration only. |
| Onset of Action | Intravenous: within 5 minutes. |
| Duration of Action | Approximately 4-6 hours for diagnostic imaging effect. |
Not applicable (diagnostic agent, not therapeutic); refer to imaging protocol.
| Dosage form | GAS |
| Renal impairment | No adjustment required; agent is not renally cleared. |
| Liver impairment | No adjustment required; agent is not hepatically metabolized. |
| Pediatric use | Dose per manufacturer guidelines based on body weight (0.1 mL/kg IV); not established for age <2 years. |
| Geriatric use | No specific adjustment; use with caution due to potential renal impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for XENOVIEW (XENOVIEW).
| Breastfeeding | Contraindicated during breastfeeding. M/P ratio unknown; potential for serious adverse reactions in nursing infants. |
| Teratogenic Risk | Pregnancy Category D. First trimester: Association with fetal malformations including neural tube defects and cleft palate. Second/third trimesters: Risk of fetal nephrotoxicity and oligohydramnios; premature closure of ductus arteriosus. |
| Fetal Monitoring |
■ FDA Black Box Warning
Not available.
| Serious Effects |
Known hypersensitivity to any component of the drug; history of allergic reaction to contrast agents containing gadolinium; severe renal impairment (GFR <30 mL/min/1.73 m2) unless dialysis is performed immediately after administration.
| Precautions | Risk of hypersensitivity reactions including anaphylaxis; caution in patients with severe renal impairment due to increased risk of nephrogenic systemic fibrosis (NSF); avoid extravasation as it may cause tissue irritation. |
Loading safety data…
| Monitor fetal ultrasound for amniotic fluid volume and ductus arteriosus patency. Maternal renal function and blood pressure should be assessed regularly. |
| Fertility Effects | May impair female fertility by affecting ovarian function. Male fertility potentially reduced due to spermatogenic disruption. |